BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...and OpkoPfizer Inc. (NYSE:PFE) and Opko Health Inc. (NASDAQ:OPK) said FDA accepted a BLA for Somatrogon...
...– Leptin receptorPCSK1 – Proprotein convertase subtilisin/kexin type 1POMC – Proopiomelanocortin BC Staff HGH-CTP, Lagova, somatrogon (MOD-4023, PF-06836922) Myriad...
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...Pfizer, Opko meets in Phase IIIPfizer Inc. (NYSE:PFE) and Opko Health Inc. (NASDAQ:OPK) said once-weekly somatrogon...
BioCentury | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

...another Pfizer rare disease program for a stature-related disorder: human growth hormone (hGH) agonist somatrogon (PF-06836922...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...OPH1003 trials to treat wet age-related macular degeneration (AMD) Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) hGH-CTP...
BioCentury | Jan 6, 2017
Clinical News

hGH-CTP: Ph III data

...double-blind, international Phase III trial in 203 adults with GHD showed that once-weekly injections of hGH-CTP...
...further statistical review and a modified analysis will show significant differentiation between hGH-CTP and placebo. hGH-CTP...
...Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lagova , hGH-CTP ( PF-06836922 , MOD-4023...
BioCentury | Jan 5, 2017
Clinical News

hGH-CTP: Ph III started

...Opko began an open-label, U.S. Phase III trial to evaluate once-weekly subcutaneous hGH-CTP vs. once-daily subcutaneous...
...Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lagova , hGH-CTP ( PF-06836922 , MOD-4023...
...IGF-1) levels and IGF binding protein 3 (IGFBP3) levels Status: Phase III started Milestone: NA Julian Zhu hGH-CTP Lagova MOD-4023 PF-06836922 Opko...
BioCentury | Dec 30, 2016
Clinical News

Opko GHD candidate fails Phase III study in adults

...Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) on Friday reported its long-acting human growth hormone (hGH) analog hGH-CTP...
...trial to treat adults with growth hormone deficiency. The study evaluated the effect of weekly hGH-CTP...
...company is “optimistic” that further statistical review and modified analysis will show significant differentiation between hGH-CTP...
BioCentury | Oct 26, 2015
Clinical News

Lagova: Phase II data

...53 treatment-naive children ages 3-11 with GHD showed that once-weekly 0.25, 0.48 and 0.66 mg/kg hGH-CTP...
...led to no treatment-related serious or unexpected adverse events, clinically significant local tolerability issues or hGH-CTP...
...Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lagova , hGH-CTP ( PF-06836922 , MOD-4023...
BioCentury | Jul 20, 2015
Clinical News

Lagova: Completed Phase III enrollment

...Opko completed enrollment in a double-blind, placebo-controlled, international Phase III trial evaluating once-weekly hGH-CTP for 26...
...Miami, Fla. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lagova , hGH-CTP ( PF-06836922 , MOD-4023...
BioCentury | Jul 7, 2015
Top Story

Versartis rises after FDA removes clinical hold

...NYSE:OPK) gained $0.57 to $16.82. In December, Opko granted Pfizer Inc. (NYSE:PFE) a license to hGH-CTP...
Items per page:
1 - 10 of 34